# Indegene (NSE: INDGN) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/INDGN · Pivot · prices to 22 Oct 2026

Indegene (NSE: INDGN) closed at ₹577.95 on 22 Oct 2026, down 1.15% on the day. With a market capitalisation of ₹13,926 Cr, it ranks 462nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Health Information Services.

At its last close the stock traded at 34.8× trailing earnings, against a return on equity of 12.8% in FY26. Over the past year the share price has risen 8.6%. Its 52-week range is ₹414.50 (23 Mar 2026) to ₹627.00 (29 Sep 2026); the last close is 7.8% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹1,063 Cr (+39.7% year on year) and net profit ₹116 Cr (−0.2%), on a consolidated basis.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹577.95 |
| Market cap | ₹13,926 Cr |
| P/E (trailing) | 34.8 |
| ROE | 12.8% (FY26) |
| ROCE | 16.0% (FY26) |
| Debt to equity | 0 |
| 52-week high | ₹627.00 (29 Sep 2026) |
| 52-week low | ₹414.50 (23 Mar 2026) |
| 1-year return | +8.6% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹1,063 Cr | +39.7% | ₹116 Cr | −0.2% | ₹4.84 |
| Q4 FY26 | ₹1,003 Cr | +32.8% | ₹80 Cr | −32.2% | ₹3.32 |
| Q3 FY26 | ₹942 Cr | +30.8% | ₹103 Cr | −6.2% | ₹4.29 |
| Q2 FY26 | ₹804 Cr | +17.1% | ₹102 Cr | +11.3% | ₹4.26 |
| Q1 FY26 | ₹761 Cr | +12.5% | ₹116 Cr | +32.7% | ₹4.86 |
| Q4 FY25 | ₹756 Cr | +12.3% | ₹118 Cr | +24.1% | ₹4.91 |
| Q3 FY25 | ₹720 Cr | +7.0% | ₹110 Cr | +11.4% | ₹4.59 |
| Q2 FY25 | ₹687 Cr | +8.0% | ₹92 Cr | +22.3% | ₹3.84 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY26 | ₹3,511 Cr | ₹401 Cr |
| FY25 | ₹2,839 Cr | ₹407 Cr |
| FY24 | ₹2,590 Cr | ₹337 Cr |
| FY23 | ₹2,306 Cr | ₹266 Cr |
| FY22 | ₹1,665 Cr | ₹163 Cr |

## Shareholding (30 Jun 2026)

- Foreign institutions: 9.91%
- Domestic institutions: 8.74%
- Non-institutions: 81.34%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Jubilant Pharmova](https://app.pivotnow.in/stock/JUBLPHARMA) | ₹930.80 | ₹14,826 Cr | 37.1 | — |
| [Dr. Agarwal's Health Care](https://app.pivotnow.in/stock/AGARWALEYE) | ₹459.10 | ₹14,553 Cr | — | — |
| [Vijaya Diagnostic Centre](https://app.pivotnow.in/stock/VIJAYA) | ₹1,382.60 | ₹14,239 Cr | 82.5 | — |
| [Natco Pharma](https://app.pivotnow.in/stock/NATCOPHARM) | ₹785.00 | ₹14,060 Cr | 9.9 | — |
| [Concord Biotech](https://app.pivotnow.in/stock/CONCORDBIO) | ₹1,298.00 | ₹13,579 Cr | 52.4 | — |
| [Marksans Pharma](https://app.pivotnow.in/stock/MARKSANS) | ₹295.80 | ₹13,405 Cr | 32.1 | — |

## Questions and answers

### What is the share price of Indegene today?

Indegene (NSE: INDGN) last closed at ₹577.95 on 22 Oct 2026. Its 52-week high is ₹627.00 and its 52-week low is ₹414.50.

### What is the market cap of Indegene?

Indegene's market capitalisation is ₹13,926 Cr (₹13,926 Cr) at the 22 Oct 2026 close, ranking 462nd among the NSE companies Pivot tracks.

### What is the P/E ratio of Indegene?

Indegene trades at a trailing P/E of 34.8. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 37.1.

### What is the ROE and ROCE of Indegene?

Return on equity was 12.8% in FY26 and return on capital employed was 16.0% in FY26 (consolidated figures).

### Is Indegene a debt-free company?

Indegene is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### What were Indegene's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Indegene reported revenue of ₹1,063 Cr, +39.7% year on year, and net profit of ₹116 Cr, −0.2% year on year.

### How has Indegene stock performed over the last year?

Indegene's share price has risen 8.6% over the past year, +17.3% over three months and −2.9% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Indegene?

As of 30 Jun 2026: foreign institutions 9.91%, domestic institutions 8.74%, non-institutions 81.34%.

### Who are Indegene's competitors?

The listed Pharma & Healthcare companies closest to Indegene by market cap are Jubilant Pharmova, Dr. Agarwal's Health Care, Vijaya Diagnostic Centre, Natco Pharma, Concord Biotech and Marksans Pharma.

### Is Indegene a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Indegene's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on INDGN against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.